Endocrinology specialist Dr Preethi Dissanayake discusses this uncommon presentation, in the latest in our series on ...

The Acromegaly Consensus Group considered many of the advances that have occurred in the management of acromegaly over the past 10 years. First, the growth hormone receptor antagonist pegvisomant ...

Acromegaly is due to hypersecretion of growth hormone and insulin-like growth factor I (IGF-I). The aim of treatment is to limit this excess secretion and to reduce morbidity and mortality.

Affected populations: Acromegaly is estimated to affect approximately 50 to 70 people out of every million. However, the true figure may be higher, as the symptoms develop slowly and thus may go ...

The following is a summary of “Knowledge and attitudes of primary care physicians regarding acromegaly: a survey study with ...

Paltusotine hydrochloride is under clinical development by Crinetics Pharmaceuticals and currently in Pre-Registration for Acromegaly.